What is Alzamend Neuro Profitability Rank?
Alzamend Neuro has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Alzamend Neuro's Operating Margin % for the quarter that ended in Jan. 2024 was %. As of today, Alzamend Neuro's Piotroski F-Score is 2.
Competitive Comparison of Alzamend Neuro's Profitability Rank
For the Biotechnology subindustry, Alzamend Neuro's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's Profitability Rank falls into.
Alzamend Neuro Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Alzamend Neuro has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Alzamend Neuro's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Alzamend Neuro has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Alzamend Neuro (Alzamend Neuro) Business Description
Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
| Ault Milton C Iii |
10 percent owner |
11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141 |
| David J Katzoff |
officer: Chief Operating Officer |
201 SHIPYARD WAY, NEWPORT BEACH CA 92663 |
| Stephan Jackman |
director, officer: Chief Executive Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Lynne Fahey Mcgrath |
director |
28145 CEDAR POINT RD., EASTON MD 21601 |
| Mark Gustafson |
director |
10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9 |
| William B. Horne |
director |
C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626 |
| Henry Carl Nisser |
director, officer: Exec VP and General Counsel |
100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017 |
| Kenneth S Cragun |
officer: SVP of Finance |
3775 CHIPPEWA CIRCLE, CORONA CA 92881 |
| Jeffrey Oram |
director |
15 ORCHARD STREET, MENDHAM NJ 07945 |
| Escalona Lien |
officer: Chief Financial Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Andrew H. Woo |
director |
2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your